Skip to main content


Page 1 of 4

  1. The prevalence, clinical characteristics, and outcomes of invasive pulmonary aspergillosis in patients with severe community-acquired pneumonia (CAP) in intensive care units remain underestimated because of th...

    Authors: Wei-Chun Lee, Che-Chia Chang, Meng-Chin Ho, Chieh-Mo Lin, Shaw-Woei Leu, Chin-Kuo Lin, Yu-Hung Fang, Shu-Yi Huang, Yu-Ching Lin, Min-Chun Chuang, Tsung-Ming Yang, Ming-Szu Hung, Yen-Li Chou, Ying-Huang Tsai and Meng-Jer Hsieh
    Citation: Pneumonia 2024 16:10
  2. In primary care, identifying pneumonia events in people with chronic obstructive pulmonary disease (COPD) may be challenging due to similarities in symptoms with COPD exacerbations and lack of diagnostic testi...

    Authors: Alexander J. Adamson, Constantinos Kallis, Ian Douglas and Jennifer K. Quint
    Citation: Pneumonia 2024 16:8
  3. Leprosy reactions often require prolonged high-dose steroids or immunosuppressive drugs, putting patients at risk of Pneumocystis jirovecii pneumonia (PJP). However, no PJP cases are reported, possibly due to dap...

    Authors: Nuria Ramírez-Perea, Claudia Moran-Castaño and Jose A. Perez-Molina
    Citation: Pneumonia 2024 16:6
  4. Klebsiella pneumoniae has become one of the major threats to public health as it causes nosocomial and community-acquired infections like lobar pneumonia. This infection causes acute inflammation in the lung, cha...

    Authors: Patrick Hervé Diboue Betote, Esther Del Florence Ndedi Moni, Sonia Raïssa Gayap Matchuenkam, Sandrine Suzanne Bayengue Beack, Rodrigue Fifen, Raogo Ouedraogo, Gabriel A. Agbor, Rasmané Semde, Nga Nnanga and Maximilienne Ascension Nyegue
    Citation: Pneumonia 2024 16:5
  5. This study aimed to examine the utility of simultaneously performed the Film Array pneumonia panels (pneumonia panels) and Gram staining with the same specimens and evaluate their effect on antimicrobial selec...

    Authors: Hiroshi Matsuura, Koudai Arimoto, Yoshihito Takahashi and Masafumi Kishimoto
    Citation: Pneumonia 2024 16:4
  6. To design a randomized clinical trial to assess the efficacy and safety of favipiravir in patients with COVID-19 disease with pneumonia.

    Authors: Juan P. Horcajada, Rebeca Aldonza, Mónica Real, Silvia Castañeda-Espinosa, Elena Sendra, Joan Gomez-Junyent, Inmaculada López-Montesinos, Silvia Gómez-Zorrilla, Silvia Briansó, Montserrat Duran-Taberna, Andrés Fernández, Cristina Tarragó and Teresa Auguet-Quintillá
    Citation: Pneumonia 2024 16:3
  7. Persistent respiratory symptoms following Coronavirus Disease 2019 (COVID-19) are associated with residual radiological changes in lung parenchyma, with a risk of development into lung fibrosis, and with impai...

    Authors: Jan Mizera, Samuel Genzor, Milan Sova, Ladislav Stanke, Radim Burget, Petr Jakubec, Martin Vykopal, Pavol Pobeha and Jana Zapletalová
    Citation: Pneumonia 2024 16:2
  8. Toll-like receptor 4 (TLR4) signaling mediates sustained systemic inflammation in(COVID)-19 patients. We aimed to assess the serum levels of sTLR4 and sCD14 as negative regulators of Toll like receptor signali...

    Authors: Maha E. Houssen, Marwa O. Elmaria, Dina Badr, Rasha El-Mahdy, Mayada A. Ghannam, Shaimaa El-Ashwah, May Denewer and Metwaly Ibrahim Mortada
    Citation: Pneumonia 2024 16:1
  9. Pneumococcal community-acquired pneumonia (P-CAP) is a major cause of morbidity and hospitalization. Several host genetics factors influencing risk of pneumococcal disease have been identified, with less infor...

    Authors: Lucía Boix-Palop, María J. Arranz, Anna Sangil, Beatriz Dietl, Mariona Xercavins, Josefa Pérez and Esther Calbo
    Citation: Pneumonia 2023 15:18
  10. The Novel Coronavirus disease (COVID-19) pandemic has become a global threat. Determining the time to recovery from COVID-19 is intended to assist healthcare professionals in providing better care, and plannin...

    Authors: Maru Zewdu Kassie, Molalign Gualu Gobena, Yihenew Mitiku Alemu and Awoke Seyoum Tegegne
    Citation: Pneumonia 2023 15:17
  11. Current microbiological tests fail to identify the causative microorganism in more than half of all pneumonia cases. We explored biomarkers that could be used for differentiating between bacterial and viral pn...

    Authors: Taiga Miyazaki, Kiyoyasu Fukushima, Kohji Hashiguchi, Shotaro Ide, Tsutomu Kobayashi, Toyomitsu Sawai, Kazuhiro Yatera, Yoshihisa Kohno, Yuichi Fukuda, Yoji Futsuki, Yuichi Matsubara, Hironobu Koga, Tomo Mihara, Eisuke Sasaki, Nobuyuki Ashizawa, Tatsuro Hirayama…
    Citation: Pneumonia 2023 15:16
  12. Respiratory pathogens, including SARS-CoV-2, can cause pulmonary structural damage and physiologic impairment, which may increase the risk of subsequent lower respiratory tract infections (LRTI). Prior hospita...

    Authors: Katia J. Bruxvoort, Heidi Fischer, Joseph A. Lewnard, Vennis X. Hong, Magdalena Pomichowski, Lindsay R. Grant, Luis Jódar, Bradford D. Gessner and Sara Y. Tartof
    Citation: Pneumonia 2023 15:15
  13. Thymosin drugs are commonly used for the treatment of viral infections due to their immunomodulatory effects. The comprehensive clinical efficacy of Thymalfasin therapy for COVID-19 associated pneumonia is not...

    Authors: Zirui Wang, Cong Wang, Xiaohua Fei, Haixing Wu, Peiqin Niu and Changxing Shen
    Citation: Pneumonia 2023 15:14
  14. Although the association between living in the vicinity of a goat farm and the occurrence of pneumonia is well-documented, it is unclear whether the higher risk of pneumonia in livestock dense areas is season-...

    Authors: C. Joris Yzermans, Youri P. Moleman, Peter Spreeuwenberg, Mark M.J. Nielen, Michel L.A. Dückers, Lidwien A.M. Smit and Christos Baliatsas
    Citation: Pneumonia 2023 15:13
  15. Pneumococcal conjugate vaccines (PCVs) provide protection against vaccine-type pneumococcal disease in both children and adults. Growing evidence suggests that PCVs also reduce pneumonia and lower respiratory ...

    Authors: Eileen M. Dunne, Marta C. Nunes, Mary P. E. Slack, Christian Theilacker and Bradford D. Gessner
    Citation: Pneumonia 2023 15:10
  16. Pneumonia is the most serious form of acute respiratory infection and Streptococcus pneumoniae is a leading cause of pediatric bacterial pneumonia. Pneumococcal conjugate vaccines were introduced in the United St...

    Authors: Tianyan Hu, Eric M. Sarpong, Yan Song, Nicolae Done, Qing Liu, Esteban Lemus-Wirtz, James Signorovitch, Salini Mohanty and Thomas Weiss
    Citation: Pneumonia 2023 15:8
  17. Since the introduction of higher valency pneumococcal conjugate vaccines in 2009, recent estimates on the economic burden of pediatric pneumococcal disease (PD) in Germany have been lacking. This study estimat...

    Authors: Tianyan Hu, Bélène Podmore, Rosemarie Barnett, Dominik Beier, Wolfgang Galetzka, Nawab Qizilbash, Dennis Heckl, Timo Boellinger and Jessica Weaver
    Citation: Pneumonia 2023 15:7
  18. The lungs are an immunologically unique environment; they are exposed to innumerable pathogens and particulate matter daily. Appropriate clearance of pathogens and response to pollutants is required to prevent...

    Authors: Filiz T. Korkmaz and Katrina E. Traber
    Citation: Pneumonia 2023 15:4
  19. With the high frequency of acute respiratory infections in children worldwide, particularly so in low-resource countries, the development of effective diagnostic support is crucial. While pulse oximetry has be...

    Authors: Maheen Sheikh, Huzaifa Ahmad, Romesa Ibrahim, Imran Nisar and Fyezah Jehan
    Citation: Pneumonia 2023 15:3
  20. Pneumococcal disease is a leading cause of communicable disease morbidity and mortality globally. We aimed to estimate invasive pneumococcal disease (IPD), pneumococcal pneumonia (PP) and all-cause pneumonia (...

    Authors: Salini Mohanty, Bélène Podmore, Ana Cuñado Moral, Ian Matthews, Eric Sarpong, Alessandra Lacetera and Nawab Qizilbash
    Citation: Pneumonia 2023 15:2
  21. There is a knowledge gap of specific characteristics linked to disease severity of the different COVID-19 waves, especially in underserved populations. We compared the demographic and clinical factors associat...

    Authors: Hye Won Shin, Alecia James, Theresa Feng, Lillian Chow and Robert Foronjy
    Citation: Pneumonia 2022 14:8
  22. A mixed pulmonary infection of Mycobacterium bacteremicum and three different isolates of nontuberculous mycobacteria (NTM) is an unusual clinical manifestation and have not yet been indicated. In this case repor...

    Authors: Morteza Masoumi, Fatemeh Sakhaee, Mohammad Reza Zolfaghari, Samira Tarashi, Fatemeh Rahimi Jamnani, Farzam Vaziri, Seyed Davar Siadat and Abolfazl Fateh
    Citation: Pneumonia 2022 14:7
  23. Surveillance for respiratory syncytial virus (RSV) likely captures just a fraction of the burden of disease. Understanding the burden of hospitalizations and disparities between populations can help to inform ...

    Authors: Zhe Zheng, Joshua L. Warren, Eugene D. Shapiro, Virginia E. Pitzer and Daniel M. Weinberger
    Citation: Pneumonia 2022 14:6
  24. Pneumonia is a major cause of morbidity and mortality in children under five. Antibiotic treatment must be started immediately in children with pneumonia. The irrational use of antibiotics may increase morbidi...

    Authors: Christine Joy Abeja, Vallence Niyonzima, John Paul Byagamy and Celestino Obua
    Citation: Pneumonia 2022 14:3
  25. Community-acquired pneumonia (CAP) is the most common cause of acute respiratory distress syndrome (ARDS). Although previous studies have suggested that macrolide therapy is beneficial for ARDS, its benefit fo...

    Authors: Jun Suzuki, Yusuke Sasabuchi, Shuji Hatakeyama, Hiroki Matsui, Teppei Sasahara, Yuji Morisawa, Toshiyuki Yamada, Kiyohide Fushimi and Hideo Yasunaga
    Citation: Pneumonia 2022 14:1
  26. In the Netherlands, an increased risk of community-acquired pneumonia (CAP) has been reported for adults living near goat and poultry farms. Previous results of respiratory microbiome studies in hospitalized C...

    Authors: Inge Roof, Arianne B. van Gageldonk-Lafeber, Tizza P. Zomer, Yolande M. Vermeeren, Peter C. Wever and Wim van der Hoek
    Citation: Pneumonia 2021 13:13
  27. Drug-induced pneumonia (d-pneumonia) and bacterial pneumonia (b-pneumonia) are often difficult to differentiate; therefore, this study examined the possibility of differentiating them using serum biomarkers.

    Authors: Yuko Waseda, Masahide Yasui, Kousuke Kurokawa, Ryo Chikazawa, Toshihiro Takeda, Miho Mitsui, Tomoaki Sonoda, Makiko Yamaguchi, Satoshi Watanabe, Hazuki Takato, Yukari Ichikawa, Yukihiro Umeda, Masaki Anzai, Hiroshi Ueda, Kazuo Kasahara and Tamotsu Ishizuka
    Citation: Pneumonia 2021 13:11
  28. Pneumococcal pneumonia is the leading cause of under-five mortality globally. The surveillance of pneumococcal serotypes is therefore vital for informing pneumococcal vaccination policy and programmes. Pneumoc...

    Authors: Alex J. J. Lister, Cheng Foh Le, Eddy Seong Guan Cheah, Mohd Nasir Mohd Desa, David W. Cleary and Stuart C. Clarke
    Citation: Pneumonia 2021 13:9
  29. Bacteria and respiratory viruses co-occur in the nasopharynx, and their interactions may impact pathogenesis of invasive disease. Associations of viruses and bacteria in the nasopharynx may be affected by HIV.

    Authors: Tila Khan, Ranjan Saurav Das, Amrita Chaudhary, Jyotirmoy Chatterjee and Sangeeta Das Bhattacharya
    Citation: Pneumonia 2021 13:8
  30. Prophylactic administration of antipyretics at the time of immunization seems to decrease some side effects, however reduced immune responses have been reported in some studies. This systematic review aimed to...

    Authors: Eleni Koufoglou, Georgia Kourlaba and Athanasios Michos
    Citation: Pneumonia 2021 13:7
  31. Pneumonia is a leading cause of death in Malaysia. Whilst many studies have reported the aetiology of pneumonia in Western countries, the epidemiology of pneumonia in Malaysia remains poorly understood. As car...

    Authors: Denise E. Morris, Hannah McNeil, Rebecca E. Hocknell, Rebecca Anderson, Andrew C. Tuck, Serena Tricarico, Mohd Nor Norazmi, Victor Lim, Tan Cheng Siang, Patricia Kim Chooi Lim, Chong Chun Wie, David W. Cleary, Ivan Kok Seng Yap and Stuart C. Clarke
    Citation: Pneumonia 2021 13:6
  32. Due to high risk of mortality, children with comorbidities are typically excluded from trials evaluating pneumonia treatment. Understanding heterogeneity of outcomes among children with pneumonia and comorbidi...

    Authors: Amy Sarah Ginsburg, Tisungane Mvalo, Jun Hwang, Melda Phiri, Eric D. McCollum, Madalitso Maliwichi, Robert Schmicker, Ajib Phiri, Norman Lufesi and Susanne May
    Citation: Pneumonia 2021 13:3
  33. Herpes simplex virus (HSV) is commonly associated with oro-facial and genital manifestations. It rarely causes encephalitis and even less commonly, in heavily immunosuppressed patients, visceral disease or bro...

    Authors: Johannes Sumer, Frederike Waldeck, Nadja Fischer, Christina Appenzeller, Markus Koster, Martin Früh and Werner C. Albrich
    Citation: Pneumonia 2021 13:1

Annual Journal Metrics

  • 2022 Citation Impact
    6.8 - 2-year Impact Factor
    5.4 - 5-year Impact Factor

    2023 Speed
    13 days submission to first editorial decision for all manuscripts (Median)
    122 days submission to accept (Median)

    2023 Usage 
    274 Altmetric mentions